查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984134

數位生物標記市場：按組件、生物標記類型、功能、治療領域、應用和最終用戶分類——2026年至2032年全球市場預測

Digital Biomarkers Market by Component, Biomarker Type, Functionality, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

數位生物標記市場預計到 2025 年將達到 23.6 億美元，到 2026 年將成長到 26.1 億美元，到 2032 年將達到 49.5 億美元，年複合成長率為 11.16%。

主要市場統計數據
基準年 2025 23.6億美元
預計年份：2026年 26.1億美元
預測年份 2032 49.5億美元
複合年成長率 (%) 11.16%

數位生物標記的興起是推動個人化醫療轉型和臨床洞察創新的驅動力。

隨著數位生物標記重新定義病患監測、診斷和治療方法方案的製定，醫療保健產業正經歷一場根本性的變革。透過先進的感測器、穿戴式裝置和植入式裝置收集生理和行為數據，這些新的指標使臨床醫生能夠持續而非間斷地評估患者的健康狀況。從依賴間斷檢查室測量和影像學檢查的傳統生物標記到數位生物標記的演變，標誌著疾病檢測、追蹤和治療方式的模式轉移。

下一波創新浪潮：技術進步與監管突破塑造數位生物標記的未來

在技​​術突破、監管進步和患者期望不斷變化等因素的推動下，數位生物標記領域正經歷著一場變革。感測器小型化和能源效率提升方面的突破，拓展了可在臨床環境之外收集的生理訊號範圍。穿戴式裝置即時採集數據，能夠持續監測生命徵象、活動模式和睡眠指標，為早期療育和更具針對性的治療方案製定創造了機會。

評估 2025 年美國關稅政策對數位生物標記開發供應鏈韌性和零件籌資策略的溢出效應。

美國新關稅的實施為數位生物標記設備及其組件的開發人員和製造商帶來了挑戰和機會。進口感測器、微電子產品和先進材料的關稅提高，正在推動籌資策略和供應鏈結構的變革。為了因應這些變化，企業正在探索替代採購途徑，並實現供應商多元化，以緩解成本壓力。

從觀點分析數位生物標記生態系統，包括其組成部分、功能和治療重點。

對數位生物標記生態系統的多方面觀點檢驗了六個關鍵的細分標準，每個標準都對市場動態和技術發展軌跡提供了細緻的見解。對各組成部分的分析表明，該系統存在硬體和軟體二分法，其中硬體又可細分為植入式裝置、感測器和穿戴式裝置。穿戴式裝置可進一步細分為健身手環和智慧型手錶。這種區分凸顯了感測器外形規格如何影響資料可靠性和使用者接受度；小型植入式裝置更適合持續的生理監測，而消費性穿戴裝置則優先考慮易用性和使用者參與度。

該計畫旨在分析全球數位生物標記市場中不同地區的採用率差異，並專注於監管協調和創新叢集。

區域趨勢反映了監管環境、醫療基礎設施和投資環境的差異，對數位生物標記的應用和成熟起著至關重要的作用。在北美，創新中心引領潮流，主導科技公司與醫療服務提供者之間強力的夥伴關係；而在拉丁美洲，試驗計畫正在探索，旨在將遠端監測能力擴展到資源匱乏的地區。該地區對以患者為中心的價值提案的關注，正在加速醫保報銷方面的對話，並建立新的醫療服務模式。

介紹透過策略合作和技術融合推動數位生物標記整合的主要企業。

主要企業正在製定策略路線圖，以保持其領先地位，並加速將數位生物標記整合到主流醫療保健中。科技巨頭正透過收購專業感測器Start-Ups來擴展其設備產品組合，並透過與數據分析公司合作來增強人工智慧 (AI) 能力。成熟的醫療設備製造商正在將數位終端整合到其現有平台中，以提高臨床試驗數據的精細度並實現遠端病人參與。

透過互通性、病人參與和供應鏈韌性來維持競爭優勢的策略挑戰

產業領導企業必須採取多管齊下的方法，才能最大限度地利用數位生物標記帶來的機遇，並駕馭日益複雜的生態系統。投資於符合新資料交換標準的互通平台，可以簡化與電子健康記錄和分析工具的整合，從而加快獲得洞見的速度。與監管機構合作，優先建立嚴格的檢驗框架，可確保數位終點符合臨床試驗和報銷要求，從而促進更廣泛的認可。

透過結合一手訪談、文獻分析和資料三角驗證，我們對數位生物標記有了全面的了解。

本分析整合了嚴謹的混合方法研究途徑所獲得的洞見。主要研究包括對50多位相關人員的深入訪談，其中包括醫療設備製造商、軟體開發商、醫療服務提供者和監管專家。這些訪談揭示了目前的檢驗實踐、商業化策略以及他們認為的應用障礙。

整合數位生物標記創新和協作框架，為醫療保健轉型規劃道路。

數位生物標記體現了技術創新與臨床需求的融合，為改善患者照護、提高藥物研發效率以及變革醫療服務模式開闢了前所未有的機會。連續感測、先進分析和以患者為中心的設計理念的整合，正在重新定義我們監測健康、診斷疾病和最佳化治療方法的方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 數位生物標記市場：按組件分類

  • 硬體
    • 嵌入式裝置
    • 感應器
    • 穿戴式裝置
      • 健身手環
      • 智慧型手錶
  • 軟體

第9章：按生物標誌類型分類的數位生物標記市場

  • 活動類型
  • 被動的

第10章：數位生物標記市場：功能

  • 連續型
  • 事件驅動
  • 常

第11章 數位生物標記市場：依治療領域分類

  • 循環系統
    • 心律不整
    • 心臟衰竭
  • 內分泌學
    • 糖尿病
    • 甲狀腺疾病
  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 乳癌
    • 攝護腺癌
  • 呼吸內科

第12章 數位生物標記市場：依應用分類

  • 疾病診斷
  • 藥物發現
  • 病患監測

第13章 數位生物標記市場：依最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 醫院和診所
  • 製藥公司

第14章 數位生物標記市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：數位生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 數位生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國數位生物標記市場

第18章：中國數位生物標記市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ActiGraph, LLC
  • Adherium Limited
  • Altoida, Inc.
  • Amgen Inc.
  • Aural Analytics, Inc. by Linus Health, Inc.
  • Biofourmis Pte. Ltd.
  • Biogen Inc.
  • Brainomix Limited
  • Chugai Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Empatica Inc.
  • F. Hoffmann-La Roche Ltd.
  • Feel Therapeutics Inc.
  • GERO PTE. LTD.
  • Huma Therapeutics Limited
  • ICON PLC
  • IXICO PLC
  • Koneksa Health Inc.
  • Medable Inc.
  • Owkin, Inc.
  • Sonde Health, Inc
  • Teva Pharmaceutical Industries Ltd.
  • Verily Life Sciences, LLC
  • VivoSense, Inc
Product Code: MRR-5C6F41F5AF45

The Digital Biomarkers Market was valued at USD 2.36 billion in 2025 and is projected to grow to USD 2.61 billion in 2026, with a CAGR of 11.16%, reaching USD 4.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.36 billion
Estimated Year [2026] USD 2.61 billion
Forecast Year [2032] USD 4.95 billion
CAGR (%) 11.16%

Navigating the Emergence of Digital Biomarkers as a Transformational Force in Personalized Healthcare and Clinical Insight Innovation

The healthcare sector is experiencing a fundamental shift as digital biomarkers redefine the landscape of patient monitoring, diagnostics, and therapeutic development. By capturing physiological and behavioral data through sophisticated sensors, wearables, and implantable devices, these novel indicators are enabling clinicians to assess health status continuously rather than episodically. The evolution from traditional biomarkers, which rely on intermittent laboratory measurements or imaging, to digital biomarkers represents a paradigm change in how diseases are detected, tracked, and treated.

In parallel, advancements in data analytics, machine learning algorithms, and cloud computing infrastructures have accelerated the ability to extract meaningful insights from high-volume, high-velocity streams of patient data. As a result, stakeholders across the healthcare continuum-from pharmaceutical companies to hospitals and research institutes-are integrating digital biomarkers into clinical trials, remote monitoring programs, and real-world evidence studies. This introduction presents the foundational concepts and underscores the transformative potential that digital biomarkers hold for enhancing patient outcomes, optimizing care pathways, and driving innovation within a more connected ecosystem.

Unveiling the Next Wave of Innovation: Technological Advances and Regulatory Breakthroughs Shaping the Future of Digital Biomarkers

The landscape of digital biomarkers is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing patient expectations. Breakthroughs in sensor miniaturization and power efficiency have expanded the range of physiological signals that can be captured outside clinical settings. Real-time data collection from wearable devices now enables continuous monitoring of vital signs, activity patterns, and sleep metrics, creating opportunities for early intervention and more adaptive treatment regimens.

At the same time, regulatory agencies have begun to recognize digital biomarkers as legitimate endpoints in clinical trials, paving the way for faster approvals and broader adoption. Harmonized guidelines are emerging that emphasize data quality, validation protocols, and patient privacy safeguards. This regulatory clarity is empowering software developers and device manufacturers to collaborate more confidently on integrated platforms, ensuring interoperability and compliance across jurisdictions.

Concurrently, patients are increasingly demanding personalized care experiences that reflect their lifestyles and preferences. The convergence of patient-centric design principles with advanced analytics is fostering the development of digital health ecosystems where individuals can actively participate in their treatment journeys. As these transformative elements converge, stakeholders must navigate the complex interplay of innovation, regulation, and user engagement to fully realize the promise of digital biomarkers.

Evaluating the Ripple Effects of 2025 US Tariff Policies on Supply Chain Resilience and Component Sourcing Strategies in Digital Biomarker Development

The implementation of new tariff measures in the United States has introduced challenges and opportunities for developers and manufacturers of digital biomarker devices and components. Imported sensors, microelectronics, and advanced materials now face increased duties, which has led to shifts in sourcing strategies and supply chain configurations. In response, companies are exploring alternate procurement channels and diversifying supplier portfolios to mitigate cost pressures.

These tariff-induced dynamics have accelerated investments in domestic manufacturing capabilities, reducing reliance on cross-border shipments and enhancing supply chain resilience. Emerging partnerships between hardware producers and contract manufacturers are focusing on localizing production hubs, incorporating lean manufacturing techniques, and optimizing component designs to minimize reliance on high-cost imports. In parallel, some stakeholders have begun redesigning device architectures to utilize semiconductors and sensor modules that are exempt from elevated duties, ensuring continued innovation while preserving cost efficiencies.

Ultimately, while the cumulative impact of tariff policy has created short-term adjustments, it has also stimulated a strategic realignment toward more agile, vertically integrated operations. Companies that can adapt swiftly to these evolving trade parameters will be better positioned to deliver next-generation digital biomarker solutions with greater responsiveness to market demands.

Dissecting the Digital Biomarker Ecosystem Through Multifaceted Component, Functionality, and Therapeutic Focus Lenses

In examining the digital biomarker ecosystem through a multidimensional lens, six primary segmentation criteria emerge, each offering nuanced insights into market dynamics and technological trajectories. Component analysis reveals a dichotomy between hardware and software, with hardware further delineated into implantables, sensors, and wearables; the latter grouping subdivides into fitness bands and smartwatches. This distinction underscores how sensor form factors influence data fidelity and user adoption, with smaller implantable devices suited for continuous physiological monitoring and consumer-grade wearables prioritizing ease of use and engagement.

Biomarker types bifurcate into active indicators, which require user engagement or specific stimuli to generate data, and passive indicators that capture signals without direct patient interaction. This differentiation shapes the design of monitoring protocols and informs validation strategies for clinical integration. Functionality segmentation highlights continuous monitoring applications that track health metrics in real time, event-driven models that trigger data capture upon detecting predefined thresholds, and periodic assessments conducted at scheduled intervals. Each modality aligns with different clinical objectives, from chronic disease management to acute event detection.

Applications extend across disease diagnostics, where digital signatures complement traditional tests; drug development programs that employ sensor-derived endpoints to assess therapeutic efficacy; and patient monitoring initiatives that facilitate remote care pathways. End users encompass academic and research institutes pioneering exploratory studies, biotechnology firms driving product innovation, hospitals and clinics integrating digital data into care delivery, and pharmaceutical companies seeking to enrich clinical trials with real-world evidence. Therapeutic areas of focus include cardiology-addressing arrhythmia and heart failure-endocrinology tackling diabetes mellitus and thyroid disorders, neurology with emphasis on Alzheimer's and Parkinson's diseases, oncology concentrating on breast and prostate cancers, and pulmonology monitoring respiratory function. Together, these layers of segmentation reveal the complexity of stakeholder needs and technological opportunities driving digital biomarker advancement.

Mapping Regional Adoption Variances Highlighting Regulatory Harmonization and Innovation Clusters Across Global Digital Biomarker Markets

Regional dynamics play a pivotal role in shaping the adoption and maturation of digital biomarkers, reflecting diverse regulatory frameworks, healthcare infrastructures, and investment landscapes. In the Americas, innovation hubs in North America lead the charge with robust partnerships between technology firms and healthcare providers, while Latin American markets explore pilot programs to extend remote monitoring capabilities across under-resourced areas. This region's emphasis on patient-centric value propositions is accelerating reimbursement dialogues and forging new care delivery models.

Across Europe, the Middle East, and Africa, regulatory convergence initiatives are fostering harmonized data governance standards, enabling cross-border clinical studies and streamlined device approvals. Western European nations are integrating digital biomarkers into national health systems, leveraging public-private collaborations to scale remote care, whereas emerging markets in the region are prioritizing low-cost sensor solutions tailored to local epidemiological profiles. In parallel, nascent digital health consortia in select Middle East and African countries are focusing on capacity building and infrastructure development.

In the Asia-Pacific, rapid digitalization, strong government support for smart healthcare initiatives, and high smartphone penetration rates are driving widespread adoption of wearable-based monitoring. Local manufacturers are optimizing production costs and customizing devices to regional biometrics, while cross-industry alliances are developing ecosystem platforms that integrate hospital networks, insurers, and technology providers. The varied pace of regulatory maturity across the region underscores the need for adaptive market entry strategies.

Profiling Leading Organizations Advancing Digital Biomarker Integration Through Strategic Alliances and Technology Convergence

Key companies are forging strategic pathways to maintain leadership and accelerate the integration of digital biomarkers into mainstream healthcare. Technology giants are expanding their device portfolios through acquisitions of specialized sensor startups and forming alliances with data analytics organizations to bolster artificial intelligence capabilities. Established medical device firms are embedding digital endpoints into legacy platforms, enhancing clinical trial data granularity and enabling remote patient engagement.

Biotechnology innovators are leveraging strategic partnerships with contract research organizations to validate digital endpoints in early-phase studies, while software vendors are investing in cloud-native architectures to ensure scalability and interoperability with electronic health record systems. Collaborative ventures between pharmaceutical companies and sensor manufacturers are focusing on co-development agreements that align therapeutic protocols with adaptive monitoring solutions. Additionally, cross-sector consortia are being established to define industry standards, promote data sharing frameworks, and advance regulatory acceptance of sensor-based outcomes.

Strategic Imperatives for Maintaining Competitive Edge Through Interoperability, Patient Engagement, and Supply Chain Resilience

Industry leaders must adopt a multi-pronged approach to capitalize on digital biomarker opportunities and navigate an increasingly complex ecosystem. Investing in interoperable platforms that adhere to emerging standards for data exchange will streamline integrations with electronic health records and analytical tools, reducing time to insight. Prioritizing rigorous validation frameworks in collaboration with regulatory bodies will ensure that digital endpoints meet clinical trial and reimbursement requirements, fostering broader acceptance.

Cultivating patient-centric design practices, including co-creation workshops with end users, will enhance device usability and long-term engagement. Leaders should also pursue partnerships across the healthcare value chain-from payors to contract research organizations-to co-develop outcome-based models that demonstrate the real-world impact of digital biomarkers. Building resilient supply chains through diversified sourcing and on-shore manufacturing capabilities will mitigate risks associated with trade policy fluctuations.

Finally, establishing robust data governance and privacy safeguards will protect patient trust and align with global regulations. By integrating these strategic imperatives, organizations can drive sustainable growth, deliver enhanced clinical insights, and unlock new value propositions in digital health.

Combining Primary Interviews, Literature Analysis, and Data Triangulation to Derive Comprehensive Digital Biomarker Insights

This analysis synthesizes insights derived from a rigorous mixed-methods research approach. Primary research included in-depth interviews with over 50 stakeholders spanning device manufacturers, software developers, healthcare providers, and regulatory experts. These conversations elucidated current validation practices, commercialization strategies, and perceived barriers to adoption.

Secondary research involved a comprehensive review of peer-reviewed journals, technical white papers, and regulatory guidance documents to ensure factual accuracy and contextual relevance. Industry databases and public filings were examined to trace recent partnerships and technology integrations, while case studies provided practical examples of digital biomarker deployment in clinical and real-world settings. All data underwent cross-validation through triangulation techniques to reinforce credibility and mitigate potential biases.

The resulting insights reflect a holistic understanding of technological trends, policy influences, and stakeholder priorities shaping the digital biomarker landscape today.

Synthesizing Digital Biomarker Innovations and Collaborative Frameworks to Chart a Course for Healthcare Transformation

Digital biomarkers represent a convergence of technological innovation and clinical necessity, unlocking unprecedented opportunities to enhance patient care, streamline drug development, and transform healthcare delivery models. The integration of continuous sensing, advanced analytics, and patient-centric design is redefining how health status is monitored, diseases are diagnosed, and therapies are optimized.

As regulatory frameworks evolve and stakeholder collaborations deepen, the potential for digital biomarkers to become standard components in clinical protocols grows ever more tangible. Organizations that embrace interoperable infrastructure, robust validation processes, and adaptive business models will be poised to lead the next wave of digital health innovation. The insights presented in this summary lay the groundwork for strategic decision-making, offering a roadmap to navigate a rapidly changing ecosystem and realize the full promise of sensor-driven healthcare transformation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Biomarkers Market, by Component

  • 8.1. Hardware
    • 8.1.1. Implantables
    • 8.1.2. Sensors
    • 8.1.3. Wearables
      • 8.1.3.1. Fitness Bands
      • 8.1.3.2. Smartwatches
  • 8.2. Software

9. Digital Biomarkers Market, by Biomarker Type

  • 9.1. Active
  • 9.2. Passive

10. Digital Biomarkers Market, by Functionality

  • 10.1. Continuous
  • 10.2. Event-Driven
  • 10.3. Periodic

11. Digital Biomarkers Market, by Therapeutic Area

  • 11.1. Cardiology
    • 11.1.1. Arrhythmia
    • 11.1.2. Heart Failure
  • 11.2. Endocrinology
    • 11.2.1. Diabetes Mellitus
    • 11.2.2. Thyroid Disorders
  • 11.3. Neurology
    • 11.3.1. Alzheimer's Disease
    • 11.3.2. Parkinson's Disease
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Prostate Cancer
  • 11.5. Pulmonology

12. Digital Biomarkers Market, by Application

  • 12.1. Disease Diagnostics
  • 12.2. Drug Development
  • 12.3. Patient Monitoring

13. Digital Biomarkers Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Biotechnology Firms
  • 13.3. Hospitals & Clinics
  • 13.4. Pharmaceutical Companies

14. Digital Biomarkers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Digital Biomarkers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Digital Biomarkers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Digital Biomarkers Market

18. China Digital Biomarkers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ActiGraph, LLC
  • 19.6. Adherium Limited
  • 19.7. Altoida, Inc.
  • 19.8. Amgen Inc.
  • 19.9. Aural Analytics, Inc. by Linus Health, Inc.
  • 19.10. Biofourmis Pte. Ltd.
  • 19.11. Biogen Inc.
  • 19.12. Brainomix Limited
  • 19.13. Chugai Pharmaceutical Co., Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. Empatica Inc.
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Feel Therapeutics Inc.
  • 19.18. GERO PTE. LTD.
  • 19.19. Huma Therapeutics Limited
  • 19.20. ICON PLC
  • 19.21. IXICO PLC
  • 19.22. Koneksa Health Inc.
  • 19.23. Medable Inc.
  • 19.24. Owkin, Inc.
  • 19.25. Sonde Health, Inc
  • 19.26. Teva Pharmaceutical Industries Ltd.
  • 19.27. Verily Life Sciences, LLC
  • 19.28. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. GCC DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 270. G7 DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. G7 DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 283. NATO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. NATO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. NATO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NATO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA DIGITAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)